

06 December, 2023

Dear REMAP-CAP site investigators and research staff,

RE: REMAP-CAP Corticosteroid Domain

We are writing to inform you of a decision made by the REMAP-CAP international trial steering committee (ITSC) in response to communication from the Data Safety Monitoring Board (DSMB).

After reviewing the results of adaptive analyses, the REMAP-CAP DSMB have notified the ITSC that **the ‘fixed-course hydrocortisone’ intervention of the Corticosteroid Domain has reached a pre-specified statistical trigger for futility** for critically ill patients with community-acquired pneumonia (CAP) without suspected or proven COVID-19. This recommendation is based on analyses of participants enrolled in this domain to August 2023, and applies to patients with and without influenza, although the proportion of participants with influenza is expected to be relatively small.

The ITSC has accepted the recommendation of the DSMB to close recruitment to this intervention, and this has been implemented in the REMAP-CAP trial database at all sites. For current patients who are enrolled in the Corticosteroid Domain and have been assigned to the fixed-duration hydrocortisone intervention, the decision to continue or discontinue the allocated intervention is at the discretion of the treating clinician.

Importantly, this statistical trigger does not apply to the other interventions within the Corticosteroid Domain. Recruitment to these interventions remains open, and we would encourage sites to continue to participate in the remaining interventions in order to answer important questions that remain unanswered about the role of corticosteroids in the treatment of severe CAP.


We will work to analyze and report these findings as soon as possible. In the interim, we request that you make this information available only to relevant clinical staff. On behalf of the REMAP-CAP ITSC we would like to thank the DSMB and the Statistical Advisory Committee for their vital work in ensuring the safety of patients enrolled in REMAP-CAP. We would also like to sincerely thank all

investigators, research staff, participants and their families who continue to support REMAP-CAP and the generation of evidence for the treatment of CAP.

Sincerely,



Dr Srinivas Murthy,
Chair, REMAP-CAP ITSC



Prof. Derek Angus
Lead, REMAP-CAP Corticosteroid Domain